Compare Boston Scientific Corporation (BSX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs United Microelectronics Corp — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while United Microelectronics Corp trades at $25.41 (market cap $59.23B). The key difference: Boston Scientific Corporation and United Microelectronics Corp are close in size by market cap, and United Microelectronics Corp pays a 1.73% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | UMC | |
|---|---|---|
Market Cap | $66.37B | $59.23B |
Sector | Health | Technology |
52-Week High | $108.14 | $28.02 |
52-Week Low | $42.63 | $6.58 |
Enterprise Value | $75.94B | $56.81B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
UMC trades at $23.46, down 3.62% over the past day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.20, exceeding expectations of $0.12, and announced a $0.41 dividend payable in August 2026. Revenue grew to $237.55 billion in 2025, though net income margin has declined from 32.1% in 2022 to 16.99% in 2025. Positive developments include mass production of silicon photonics ICs and a new 14nm eHV FinFET platform.
Outlook remains mixed with strong operational cash flow and technological advancements balanced against high valuation multiples and margin compression. Key risks include competitive pressures in semiconductor foundry markets and sensitivity to global economic cycles. Analyst consensus is cautious with 53.3% hold ratings, suggesting limited near-term upside despite solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
